Clinical trial
The Impact of Chronic Mitochondrial Antioxidant (MitoQ) Supplementation on Cardiovascular Toxicity Induced by Doxorubicin-Based Adjuvant Chemotherapy in Breast Cancer Patients: Randomized Clinical Trial
NCT05146843 is registered in ClinicalTrials.gov with D'Or Institute for Research and Education as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Impact of Chronic Mitochondrial Antioxidant (MitoQ) Supplementation on Cardiovascular Toxicity Induced by Doxorubicin-Based Adjuvant Chemotherapy in Breast Cancer Patients: Randomized Clinical Trial
- Lead sponsor
- D'Or Institute for Research and Education
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- June 2, 2022
- Completion date
- December 2, 2023
- Enrollment
- 44 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.